Journal article
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
S Masaldan, AI Bush, D Devos, AS Rolland, C Moreau
Free Radical Biology and Medicine | Published : 2019
Abstract
Perturbations in iron homeostasis and iron accumulation feature in several neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS). Proteins such as α-synuclein, tau and amyloid precursor protein that are pathologically associated with neurodegeneration are involved in molecular crosstalk with iron homeostatic proteins. Quantitative susceptibility mapping, an MRI based non-invasive technique, offers proximal evaluations of iron load in regions of the brain and powerfully predicts cognitive decline. Further, small molecules that target elevated iron have shown promise against PD and AD in preclinical studies and clinical..
View full abstractGrants
Awarded by Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone
Funding Acknowledgements
The authors would like to thank Dr. Abdel Ali Belaidi, Dr. Scott Ayton and Dr. Darius Lane (Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia) for their valuable feedback on the drafts of this manuscript. AIB is supported by funds from the National Health & Medical Research Council of Australia (GNT1103703, GNT1101533). AIB is a shareholder in Prana Biotechnology Ltd, Cogstate Ltd., Brighton Biotech LLC, Grunbiotics Pty Ltd, Eucalyptus Pty Ltd., and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd. CM has received grants from the France Parkinson charity. DD has received PHRC grants from the French Ministry of Health and research funding from the ARSLA charity, France Parkinson charity, Credit Agricole Foundation, and Horizon 2020 (Grant No. 633190) from the European Commision. He has led two pilot investigator driven studies with DFP provided for free by ApoPharma [FAIRPARK-I (NCT00943748) and SAFE-FAIR ALS-I (NCT02164253)]. He is leading two large investigator driven studies with DFP provided for free by ApoPharma [FAIRPARK-II (NCT02655315) and FAIR ALS-II (NCT03293069)]. He served on advisory boards, served as a consultant and given lectures for pharmaceutical companies such as Orkyn, Abbvie, Boston Scientific.